DSM considers alliance

June 2007
ICIS Chemical Business;6/25/2007, Vol. 2 Issue 72, p60
Trade Publication
The article reports on the proposed partnership of DSM Nederland B.V. with North China Pharmaceutical Corp. to produce and market anti-infectives in China. According to the company, the partnership will possibly put into a separate entity and partial divestments which they expect to take an impairment charges of around $147 million.


Related Articles

  • DSM and NCPC Sign Contracts to Establish Nutrition and Anti-infectives JV in Hebei. Shi, Lina // China Chemical Reporter;4/6/2009, Vol. 20 Issue 10, p10 

    The article reports that Royal DSM NV and North China Pharmaceutical Group Corp. Ltd. (NCPC Group) have signed contracts to establish joint ventures (JVs) in the areas of nutritional products and anti-infective agents in the province of Hebei, China. As part of these contracts, Royal DSM will...

  • DSM to Invest in Anti-Infectives in China. Ramesh, Deepti // Chemical Week;3/30/2009, Vol. 171 Issue 9, p23 

    The article reports on a contract signed by DSM with North China Pharmaceutical Group Corp. to establish three separate joint ventures for nutritional products and anti-infectives in China. An investment totaling $110 million would be made by DSM for the ventures. DSM has also expressed plans to...

  • North China Pharmaceutical: Changes Along with the New Medical Reform.  // China Chemical Reporter;4/26/2009, Vol. 20 Issue 12, p24 

    The article discusses how the changes of China's New Medical Reform affect the transactions of North China Pharmaceutical Co. Ltd. The company changes its focus on drug preparations instead of bulk drugs. Moreover, it cites that the company is moving its factories in the urban areas of...

  • North China Pharmaceutical to Raise R & D Ability.  // China Chemical Reporter;1/26/2009, Vol. 20 Issue 3, p8 

    The article reports on the announcement of North China Pharmaceutical Company Ltd. based in Shijiazhuang, Hebei province on January 9, 2009. The company intends to acquire a 77.84% interest in NCPC New Drug R&D Co., Ltd. from North China Pharmaceutical Group Corporation (NCPC), to strengthen its...

  • Going Dutch on vitamin deal. Robinson, Simon // European Chemical News;10/31/2005, Vol. 83 Issue 2169, p7 

    This article reports on the plan of Dutch specialty materials and life sciences group DSM to invest $164 million in its vitamins and antibiotics joint ventures with North China Pharmaceutical Group Corporation as part of an agreement revealed in November 2004. The Dutch chemicals and life...

  • Western Manufacturers Buy in China. Boswell, Clay // Chemical Market Reporter;6/7/2004, Vol. 265 Issue 23, pFR4 

    Reports on the emergence of China as an important source of low-cost active pharmaceutical ingredients. Number of Chinese active pharmaceutical ingredients manufacturing companies; Production of 1,350 different active pharmaceutical ingredients; Major players in the Chinese fine chemicals...

  • Crude penicillin pricing stabilizes.  // Chemical Market Reporter;5/9/2005, Vol. 267 Issue 19, p11 

    Reports on the stability of the global prices for crude penicillin according to DSM, the global leader in antibiotic intermediates. Decrease in prices of penicillin in 2004 which plunged the company's life science products into a loss in the fourth quarter of 2004; DSM's restructuring of its...

  • DSM invests in nutritional products firms in China.  // Chemical Market Reporter;10/31/2005, Vol. 268 Issue 15, p15 

    Reports on the plan of the chemicals firm, DSM, to invest in its vitamins and antibiotics joint ventures with North China Pharmaceutical Corp. Total value of the investment; Terms of the agreement; Benefits of the agreement for the firms.

  • DSM to Carve out Ailing Antibiotics Business. Scott, Alex // Chemical Week;6/27/2007, Vol. 169 Issue 22, p22 

    The article announces DSM's plan to restructure its antibiotics business, DSM Anti-Infectives, as a separate business unit. The plan is designed to make the business more attractive to outside parties as a potential manufacturing partner. A joint venture is set with North China Pharmaceutical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics